Objective: To determine the effectiveness of Tapentadol in cancer patients with neuropathic pain. Material and methods: A descriptive, longitudinal, observational and prospective study was carried out including patients with cancer diagnosis and neuropathic pain treated at the pain clinic between January 1, 2014 and December 31, 2019. Results: 63 patients with a mean age of 59.07 ± 11.06 years were included, of which 76.2% (n = 48) were female. In the EVERA (verbal analog scale) and DN4 (neuropathic pain in 4 questions) scales, a significant difference was observed after treatment and when Tapentadol was initially used, a lower proportion of adverse effects was observed. Conclusions: Tapentadol proved to be an equally effective tool as other treatments, both as an initial or rotation drug, and when used as first line, it had better tolerability.

Resultados: Se incluyeron 63 pacientes con una edad promedio de 59.07 ± 11.06 años, de los cuales el 76.2% (n = 48) fueron del sexo femenino. En las escalas EVERA (escala verbal analógica) y DN4 (dolor neuropático en 4 preguntas), se observó una diferencia significativa postratamiento y al usar inicialmente tapentadol se observó una menor proporción de efectos adversos. Conclusiones: El tapentadol demostró ser una herramienta igual de eficaz que otros tratamientos tanto como fármaco inicial o de rotación y usado como primera línea tuvo mejor tolerabilidad.